![Ceri Fielding](https://profiles-cardiff.imgix.net/attachments/2428?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Trosolwyg
Rwy'n Ddarlithydd mewn Firoleg o fewn y grŵp 'Imiwnoleg Firaol' a hefyd y grŵp 'Cytomegalovirus and Adenovirus Virology'. Mae fy ymchwil yn ymchwilio i ryngweithio firysau â'r system imiwnedd dynol. Yn flaenorol, rwyf wedi astudio rhyngweithiadau imiwnedd â cytomegalofirws, prif achos heintus diffygion geni a phroblem mewn cleifion trawsblaniad, a SARS-CoV-2, achos COVID-19. Rwyf bellach hefyd yn edrych ar sut mae firysau RNA sydd â photensial pandemig yn rhyngweithio â'r system imiwnedd gynhenid.
Cyhoeddiad
2024
- Litvin, U., Wang, E. C., Stanton, R. J., Fielding, C. A. and Hughes, J. 2024. Evolution of the cytomegalovirus RL11 gene family in old world monkeys and great apes. Virus Evolution 10(1), article number: veae066. (10.1093/ve/veae066)
- Hunter, L. M. et al. 2024. HCMV US2 co-opts TRC8 to degrade the endoplasmic reticulum-resident protein LMAN2L. Journal of General Virology 105(4), article number: 1980. (10.1099/jgv.0.001980)
- Li, H. et al. 2024. Human cytomegalovirus degrades DMXL1 to inhibit autophagy, lysosomal acidification, and viral assembly. Cell Host & Microbe 32(4), pp. 466-478., article number: E11. (10.1016/j.chom.2024.02.013)
2023
- Vlachava, V. et al. 2023. HCMV-secreted glycoprotein gpUL4 inhibits TRAIL-mediated apoptosis and NK cell activation. Proceedings of the National Academy of Sciences 120(49), article number: e2309077120. (10.1073/pnas.2309077120)
- Rubina, A. et al. 2023. ADAM17 targeting by human cytomegalovirus remodels the cell surface proteome to simultaneously regulate multiple immune pathways. Proceedings of the National Academy of Sciences 120(33), article number: e2303155120. (10.1073/pnas.2303155120)
- Grant, M. D. et al. 2023. Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2. JCI Insight 8(15), article number: e170681. (10.1172/jci.insight.170681)
- Ashley, C. L. et al. 2023. Suppression of MR1 by human cytomegalovirus inhibits MAIT cell activation. Frontiers in Immunology 14 (10.3389/fimmu.2023.1107497)
2022
- Fielding, C. A. et al. 2022. SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. eLife 11 (10.7554/eLife.74489)
- Wang, E. C., Fielding, C. A. and Stanton, R. J. 2022. Concerns over functional experiments, interpretation, and required controls. Journal of Clinical Investigation 132(5), article number: e157369. (10.1172/JCI157369)
- Nightingale, K. et al. 2022. Human cytomegalovirus protein RL1 degrades the antiviral factor SLFN11 via recruitment of the CRL4 E3 ubiquitin ligase complex. Proceedings of the National Academy of Sciences 119(6), article number: e2108173119. (10.1073/pnas.2108173119)
2020
- Elasifer, H. et al. 2020. Downregulation of HLA-I by the molluscum contagiosum virus mc080 impacts NK-cell recognition and promotes CD8+ T-cell evasion. Journal of General Virology 101, pp. 863-872. (10.1099/jgv.0.001417)
2018
- Patel, M., Vlachava, V., Forbes, S. K., Fielding, C. A., Stanton, R. J. and Wang, E. 2018. HCMV-encoded NK modulators: Lessons from in vitro and in vivo genetic variation. Frontiers in Immunology 9, article number: 2214. (10.3389/fimmu.2018.02214)
- Nightingale, K. et al. 2018. High-definition analysis of host protein stability during human cytomegalovirus infection reveals antiviral factors and viral evasion mechanisms. Cell Host and Microbe 24(3), pp. 447-460.e11. (10.1016/j.chom.2018.07.011)
- Wang, E. C. Y. et al. 2018. Suppression of costimulation by human cytomegalovirus promotes evasion of cellular immune defenses. Proceedings of the National Academy of Sciences 115(19), pp. 4998-5003. (10.1073/pnas.1720950115)
2017
- Stacey, M. A. et al. 2017. The antiviral restriction factor IFN-induced transmembrane protein 3 prevents cytokine-driven CMV pathogenesis. Journal of Clinical Investigation 127(4), pp. 1463-1474. (10.1172/JCI84889)
- Fielding, C. A. et al. 2017. Control of immune ligands by members of a cytomegalovirus gene expansion suppresses natural killer cell activation. eLife 6, article number: e22206. (10.7554/eLife.22206)
2016
- Murrell, I. et al. 2016. Genetic stability of BAC-deerived human cytomegalovirus during culture in vitro. Journal of Virology 90(8), pp. 3929-3943. (10.1128/JVI.02858-15)
2015
- Wilkinson, G. W. G. et al. 2015. Human cytomegalovirus: taking the strain. Medical Microbiology and Immunology 204(3), pp. 273-284. (10.1007/s00430-015-0411-4)
- Fielding, C. A. 2015. Mimicry of cytokine pathways by human herpesviruses. Future Virology 10(1), pp. 41-51. (10.2217/fvl.14.101)
2014
- Weekes, M. et al. 2014. Quantitative temporal viromics: an approach to investigate host-pathogen interaction. Cell 157(6), pp. 1460-1472. (10.1016/j.cell.2014.04.028)
- Fielding, C. A. et al. 2014. Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation. PLoS Pathogens 10(5), article number: e1004058. (10.1371/journal.ppat.1004058)
- Jones, S. A., Fraser, D. J., Fielding, C. A. and Jones, G. W. 2014. Interleukin-6 in renal disease and therapy. Nephrology Dialysis Transplantation 30(4), pp. 564-574. (10.1093/ndt/gfu233)
- Seirafian, S., Prod'homme, V., Sugrue, D., Davies, J., Fielding, C., Tomasec, P. and Wilkinson, G. W. G. 2014. Human cytomegalovirus suppresses Fas expression and function. Journal of General Virology 95(4), pp. 933-939. (10.1099/vir.0.058313-0)
- Fielding, C. A. et al. 2014. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40(1), pp. 40-50. (10.1016/j.immuni.2013.10.022)
2013
- Lauder, S. N. et al. 2013. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. European Journal of Immunology 43(10), pp. 2613-2625. (10.1002/eji.201243018)
- Fielding, C. A., Jones, G. W., Taylor, P. R., Jenkins, B. J., Topley, N. and Jones, S. A. 2013. IL-6 regulation of Th1 responses drives fibrosis in unresolved inflammation [Abstract]. Cytokine 63(3), pp. 262. (10.1016/j.cyto.2013.06.082)
2012
- Pembroke, T. et al. 2012. Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+T-cell immunity. European Journal of Immunology 42(9), pp. 2383-2394. (10.1002/eji.201142072)
- Fielding, C. A. et al. 2012. A novel human cytomegalovirus gene function targets the natural killer cell activating ligand MICA for lysosomal degradation [Abstract]. Immunology 137(S1), pp. 154. (10.1111/imm.12001)
- Fielding, C. A. 2012. Interleukin-19: a new target to aim for?. Rheumatology 51(3), pp. 399-400. (10.1093/rheumatology/ker174)
2011
- Colmont, C. S. et al. 2011. Human peritoneal mesothelial cells respond to bacterial ligands through a specific subset of Toll-like receptors. Nephrology Dialysis Transplantation 26(12), pp. 4079-4090. (10.1093/ndt/gfr217)
2010
- Stumhofer, J. S. et al. 2010. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nature Immunology 11(12), pp. 1119-1126. (10.1038/ni.1957)
- Lauder, S. N., Smart, K., Ondondo, B., Fielding, C. A., Godkin, A. J., Jones, S. A. and Gallimore, A. M. 2010. A critical role for interleukin-6 in limiting influenza-induced pathology and generating heterosubtypic immunity [Abstract]. Immunology 131(S1), pp. 186. (10.1111/j.1365-2567.2010.03390.x)
- Lin, C. et al. 2010. The HMB-PP producing capacity of the causative pathogen and local gamma delta T cell numbers predict clinical outcome from bacterial peritonitis. Immunology 131, pp. 81-82.
- Coles, B., Colmont, C. S., Fielding, C. A., Kift-Morgan, A., Hams, E., Topley, N. and Jones, S. A. 2010. Local manipulation of IL-6 trans-signaling therapeutically enhances anti-microbial host defense [Abstract]. Cytokine 52(1-2), pp. 80-81. (10.1016/j.cyto.2010.07.335)
- Li, N., McLaren, J. E., Michael, D. R., Clement, M., Fielding, C. A. and Ramji, D. P. 2010. ERK is integral to the IFN-γ-mediated activation of STAT1, the expression of key genes implicated in atherosclerosis, and the uptake of modified lipoproteins by human macrophages. The Journal of Immunology 185(5), pp. 3041-3048. (10.4049/jimmunol.1000993)
2009
- Luo, D. D., Fielding, C. A., Phillips, A. O. and Fraser, D. J. 2009. Interleukin-1 beta regulates proximal tubular cell transforming growth factor beta-1 signalling. Nephrology Dialysis Transplantation 24(9), pp. 2655-2665. (10.1093/ndt/gfp208)
2008
- Jenkins, B. J. et al. 2008. Differential roles of IL-6 and IL-11 in inflammation and tumorigenesis [Abstract]. Cytokine 43(3), pp. 243-243. (10.1016/j.cyto.2008.07.069)
- Rabe, B. et al. 2008. The role of IL6-transsignaling in acute and chronic inflammation [Abstract]. Cytokine 43(3), pp. 244-244. (10.1016/j.cyto.2008.07.073)
- Hams, E. et al. 2008. Oncostatin M receptor-β signaling limits monocytic cell recruitment in acute inflammation. Journal of Immunology 181(3), pp. 2174-2180.
- Fielding, C. A. et al. 2008. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. Journal of Immunology 181(3), pp. 2189-2195.
- Hams, E. et al. 2008. Oncostatin M receptor-beta signaling limits monocytic cell recruitment in acute inflammation. Journal of Immunology 181(3), pp. 2174-2180.
- Fielding, C. A. and Topley, N. 2008. Piece by piece: solving the puzzle of peritoneal fibrosis [Commentary]. Peritoneal Dialysis International 28(5), pp. 477-479.
2007
- Chalaris, A. et al. 2007. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood -New York- 110(6), pp. 1748-1755. (10.1182/blood-2007-01-067918)
- Coles, B., Fielding, C. A., Rose-John, S., Scheller, J., Jones, S. A. and O'Donnell, V. B. 2007. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. American Journal of Pathology 171(1), pp. 315-325. (10.2353/ajpath.2007.061078)
- Rabe, B. et al. 2007. IL6/sIL6R-transsignaling controls innate and aquired immunity [Abstract]. Cytokine 39(1), pp. 34-34. (10.1016/j.cyto.2007.07.129)
- Hams, E. et al. 2007. Oncostatin M receptor signalling regulates monocytic cell trafficking during acute inflammation [Abstract]. Cytokine 39(1), pp. 14-14. (10.1016/j.cyto.2007.07.053)
2006
- Nowell, M. A. et al. 2006. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis & Rheumatism 54(7), pp. 2084-2095. (10.1002/art.21942)
- Monslow, J. et al. 2006. Sp1 and Sp3 mediate constitutive transcription of the human hyaluronan synthase 2 gene. The Journal of Biological Chemistry 281(26), pp. 18043-18050. (10.1074/jbc.M510467200)
- Osborne, C. S., Leitner, I., Hofbauer, B., Fielding, C. A., Favre, B. and Ryder, N. S. 2006. Biological, biochemical, and molecular characterization of a new clinical Trichophyton rubrum isolate resistant to terbinafine. Antimicrobial Agents and Chemotherapy 50(6), pp. 2234-2236. (10.1128/AAC.01600-05)
- Richards, P. J. et al. 2006. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis & Rheumatism 54(5), pp. 1662-1672. (10.1002/art.21818)
2005
- Fielding, C. A. et al. 2005. Viral IL-6 blocks neutrophil infiltration during acute inflammation. The Journal of Immunology 175(6), pp. 4024-4029.
- Siebert, S., Fielding, C. A., Williams, B. D. and Brennan, P. 2005. Mutation of the extracellular domain of tumour necrosis factor receptor 1 causes reduced NF‐κB activation due to decreased surface expression. FEBS Letters 579(23), pp. 5193-5198. (10.1016/j.febslet.2005.08.037)
- McLoughlin, R. M. et al. 2005. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proceedings of the National Academy of Sciences of the United States of America (PNAS) ISSN 1091-6490 102(27), pp. 9589-9594. (10.1073/pnas.0501794102)
- Siebert, S., Amos, N., Fielding, C. A., Wang, E. C. Y., Aksentijevich, I., Williams, B. D. and Brennan, P. 2005. Reduced tumor necrosis factor signaling in primary human fibroblasts containing a tumor necrosis factor receptor superfamily 1A mutant. Arthritis & Rheumatism 52(4), pp. 1287-1282. (10.1002/art.20955)
2004
- Fielding, C. A., Siebert, S., Rowe, M. and Brennan, P. 2004. Analysis of human tumour necrosis factor receptor 1 dominant-negative mutants reveals a major region controlling cell surface expression. FEBS Letters 570(1-3), pp. 138-142. (10.1016/j.febslet.2004.06.035)
2003
- Richardson, C. J., Fielding, C., Rowe, M. and Brennan, P. 2003. Epstein-Barr virus regulates STAT1 through latent membrane protein 1. Journal of Virology 77(7), pp. 4439-4443. (10.1128/JVI.77.7.4439-4443.2003)
2001
- Fielding, C. A., Sandvej, K., Mehl, A. M., Brennan, P., Jones, M. and Rowe, M. 2001. Epstein-Barr virus LMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways. Journal of Virology 75(19), pp. 9129-9141. (10.1128/JVI.75.19.9129-9141.2001)
Articles
- Litvin, U., Wang, E. C., Stanton, R. J., Fielding, C. A. and Hughes, J. 2024. Evolution of the cytomegalovirus RL11 gene family in old world monkeys and great apes. Virus Evolution 10(1), article number: veae066. (10.1093/ve/veae066)
- Hunter, L. M. et al. 2024. HCMV US2 co-opts TRC8 to degrade the endoplasmic reticulum-resident protein LMAN2L. Journal of General Virology 105(4), article number: 1980. (10.1099/jgv.0.001980)
- Li, H. et al. 2024. Human cytomegalovirus degrades DMXL1 to inhibit autophagy, lysosomal acidification, and viral assembly. Cell Host & Microbe 32(4), pp. 466-478., article number: E11. (10.1016/j.chom.2024.02.013)
- Vlachava, V. et al. 2023. HCMV-secreted glycoprotein gpUL4 inhibits TRAIL-mediated apoptosis and NK cell activation. Proceedings of the National Academy of Sciences 120(49), article number: e2309077120. (10.1073/pnas.2309077120)
- Rubina, A. et al. 2023. ADAM17 targeting by human cytomegalovirus remodels the cell surface proteome to simultaneously regulate multiple immune pathways. Proceedings of the National Academy of Sciences 120(33), article number: e2303155120. (10.1073/pnas.2303155120)
- Grant, M. D. et al. 2023. Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2. JCI Insight 8(15), article number: e170681. (10.1172/jci.insight.170681)
- Ashley, C. L. et al. 2023. Suppression of MR1 by human cytomegalovirus inhibits MAIT cell activation. Frontiers in Immunology 14 (10.3389/fimmu.2023.1107497)
- Fielding, C. A. et al. 2022. SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. eLife 11 (10.7554/eLife.74489)
- Wang, E. C., Fielding, C. A. and Stanton, R. J. 2022. Concerns over functional experiments, interpretation, and required controls. Journal of Clinical Investigation 132(5), article number: e157369. (10.1172/JCI157369)
- Nightingale, K. et al. 2022. Human cytomegalovirus protein RL1 degrades the antiviral factor SLFN11 via recruitment of the CRL4 E3 ubiquitin ligase complex. Proceedings of the National Academy of Sciences 119(6), article number: e2108173119. (10.1073/pnas.2108173119)
- Elasifer, H. et al. 2020. Downregulation of HLA-I by the molluscum contagiosum virus mc080 impacts NK-cell recognition and promotes CD8+ T-cell evasion. Journal of General Virology 101, pp. 863-872. (10.1099/jgv.0.001417)
- Patel, M., Vlachava, V., Forbes, S. K., Fielding, C. A., Stanton, R. J. and Wang, E. 2018. HCMV-encoded NK modulators: Lessons from in vitro and in vivo genetic variation. Frontiers in Immunology 9, article number: 2214. (10.3389/fimmu.2018.02214)
- Nightingale, K. et al. 2018. High-definition analysis of host protein stability during human cytomegalovirus infection reveals antiviral factors and viral evasion mechanisms. Cell Host and Microbe 24(3), pp. 447-460.e11. (10.1016/j.chom.2018.07.011)
- Wang, E. C. Y. et al. 2018. Suppression of costimulation by human cytomegalovirus promotes evasion of cellular immune defenses. Proceedings of the National Academy of Sciences 115(19), pp. 4998-5003. (10.1073/pnas.1720950115)
- Stacey, M. A. et al. 2017. The antiviral restriction factor IFN-induced transmembrane protein 3 prevents cytokine-driven CMV pathogenesis. Journal of Clinical Investigation 127(4), pp. 1463-1474. (10.1172/JCI84889)
- Fielding, C. A. et al. 2017. Control of immune ligands by members of a cytomegalovirus gene expansion suppresses natural killer cell activation. eLife 6, article number: e22206. (10.7554/eLife.22206)
- Murrell, I. et al. 2016. Genetic stability of BAC-deerived human cytomegalovirus during culture in vitro. Journal of Virology 90(8), pp. 3929-3943. (10.1128/JVI.02858-15)
- Wilkinson, G. W. G. et al. 2015. Human cytomegalovirus: taking the strain. Medical Microbiology and Immunology 204(3), pp. 273-284. (10.1007/s00430-015-0411-4)
- Fielding, C. A. 2015. Mimicry of cytokine pathways by human herpesviruses. Future Virology 10(1), pp. 41-51. (10.2217/fvl.14.101)
- Weekes, M. et al. 2014. Quantitative temporal viromics: an approach to investigate host-pathogen interaction. Cell 157(6), pp. 1460-1472. (10.1016/j.cell.2014.04.028)
- Fielding, C. A. et al. 2014. Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation. PLoS Pathogens 10(5), article number: e1004058. (10.1371/journal.ppat.1004058)
- Jones, S. A., Fraser, D. J., Fielding, C. A. and Jones, G. W. 2014. Interleukin-6 in renal disease and therapy. Nephrology Dialysis Transplantation 30(4), pp. 564-574. (10.1093/ndt/gfu233)
- Seirafian, S., Prod'homme, V., Sugrue, D., Davies, J., Fielding, C., Tomasec, P. and Wilkinson, G. W. G. 2014. Human cytomegalovirus suppresses Fas expression and function. Journal of General Virology 95(4), pp. 933-939. (10.1099/vir.0.058313-0)
- Fielding, C. A. et al. 2014. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40(1), pp. 40-50. (10.1016/j.immuni.2013.10.022)
- Lauder, S. N. et al. 2013. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. European Journal of Immunology 43(10), pp. 2613-2625. (10.1002/eji.201243018)
- Fielding, C. A., Jones, G. W., Taylor, P. R., Jenkins, B. J., Topley, N. and Jones, S. A. 2013. IL-6 regulation of Th1 responses drives fibrosis in unresolved inflammation [Abstract]. Cytokine 63(3), pp. 262. (10.1016/j.cyto.2013.06.082)
- Pembroke, T. et al. 2012. Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+T-cell immunity. European Journal of Immunology 42(9), pp. 2383-2394. (10.1002/eji.201142072)
- Fielding, C. A. et al. 2012. A novel human cytomegalovirus gene function targets the natural killer cell activating ligand MICA for lysosomal degradation [Abstract]. Immunology 137(S1), pp. 154. (10.1111/imm.12001)
- Fielding, C. A. 2012. Interleukin-19: a new target to aim for?. Rheumatology 51(3), pp. 399-400. (10.1093/rheumatology/ker174)
- Colmont, C. S. et al. 2011. Human peritoneal mesothelial cells respond to bacterial ligands through a specific subset of Toll-like receptors. Nephrology Dialysis Transplantation 26(12), pp. 4079-4090. (10.1093/ndt/gfr217)
- Stumhofer, J. S. et al. 2010. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nature Immunology 11(12), pp. 1119-1126. (10.1038/ni.1957)
- Lauder, S. N., Smart, K., Ondondo, B., Fielding, C. A., Godkin, A. J., Jones, S. A. and Gallimore, A. M. 2010. A critical role for interleukin-6 in limiting influenza-induced pathology and generating heterosubtypic immunity [Abstract]. Immunology 131(S1), pp. 186. (10.1111/j.1365-2567.2010.03390.x)
- Lin, C. et al. 2010. The HMB-PP producing capacity of the causative pathogen and local gamma delta T cell numbers predict clinical outcome from bacterial peritonitis. Immunology 131, pp. 81-82.
- Coles, B., Colmont, C. S., Fielding, C. A., Kift-Morgan, A., Hams, E., Topley, N. and Jones, S. A. 2010. Local manipulation of IL-6 trans-signaling therapeutically enhances anti-microbial host defense [Abstract]. Cytokine 52(1-2), pp. 80-81. (10.1016/j.cyto.2010.07.335)
- Li, N., McLaren, J. E., Michael, D. R., Clement, M., Fielding, C. A. and Ramji, D. P. 2010. ERK is integral to the IFN-γ-mediated activation of STAT1, the expression of key genes implicated in atherosclerosis, and the uptake of modified lipoproteins by human macrophages. The Journal of Immunology 185(5), pp. 3041-3048. (10.4049/jimmunol.1000993)
- Luo, D. D., Fielding, C. A., Phillips, A. O. and Fraser, D. J. 2009. Interleukin-1 beta regulates proximal tubular cell transforming growth factor beta-1 signalling. Nephrology Dialysis Transplantation 24(9), pp. 2655-2665. (10.1093/ndt/gfp208)
- Jenkins, B. J. et al. 2008. Differential roles of IL-6 and IL-11 in inflammation and tumorigenesis [Abstract]. Cytokine 43(3), pp. 243-243. (10.1016/j.cyto.2008.07.069)
- Rabe, B. et al. 2008. The role of IL6-transsignaling in acute and chronic inflammation [Abstract]. Cytokine 43(3), pp. 244-244. (10.1016/j.cyto.2008.07.073)
- Hams, E. et al. 2008. Oncostatin M receptor-β signaling limits monocytic cell recruitment in acute inflammation. Journal of Immunology 181(3), pp. 2174-2180.
- Fielding, C. A. et al. 2008. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. Journal of Immunology 181(3), pp. 2189-2195.
- Hams, E. et al. 2008. Oncostatin M receptor-beta signaling limits monocytic cell recruitment in acute inflammation. Journal of Immunology 181(3), pp. 2174-2180.
- Fielding, C. A. and Topley, N. 2008. Piece by piece: solving the puzzle of peritoneal fibrosis [Commentary]. Peritoneal Dialysis International 28(5), pp. 477-479.
- Chalaris, A. et al. 2007. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood -New York- 110(6), pp. 1748-1755. (10.1182/blood-2007-01-067918)
- Coles, B., Fielding, C. A., Rose-John, S., Scheller, J., Jones, S. A. and O'Donnell, V. B. 2007. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. American Journal of Pathology 171(1), pp. 315-325. (10.2353/ajpath.2007.061078)
- Rabe, B. et al. 2007. IL6/sIL6R-transsignaling controls innate and aquired immunity [Abstract]. Cytokine 39(1), pp. 34-34. (10.1016/j.cyto.2007.07.129)
- Hams, E. et al. 2007. Oncostatin M receptor signalling regulates monocytic cell trafficking during acute inflammation [Abstract]. Cytokine 39(1), pp. 14-14. (10.1016/j.cyto.2007.07.053)
- Nowell, M. A. et al. 2006. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis & Rheumatism 54(7), pp. 2084-2095. (10.1002/art.21942)
- Monslow, J. et al. 2006. Sp1 and Sp3 mediate constitutive transcription of the human hyaluronan synthase 2 gene. The Journal of Biological Chemistry 281(26), pp. 18043-18050. (10.1074/jbc.M510467200)
- Osborne, C. S., Leitner, I., Hofbauer, B., Fielding, C. A., Favre, B. and Ryder, N. S. 2006. Biological, biochemical, and molecular characterization of a new clinical Trichophyton rubrum isolate resistant to terbinafine. Antimicrobial Agents and Chemotherapy 50(6), pp. 2234-2236. (10.1128/AAC.01600-05)
- Richards, P. J. et al. 2006. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis & Rheumatism 54(5), pp. 1662-1672. (10.1002/art.21818)
- Fielding, C. A. et al. 2005. Viral IL-6 blocks neutrophil infiltration during acute inflammation. The Journal of Immunology 175(6), pp. 4024-4029.
- Siebert, S., Fielding, C. A., Williams, B. D. and Brennan, P. 2005. Mutation of the extracellular domain of tumour necrosis factor receptor 1 causes reduced NF‐κB activation due to decreased surface expression. FEBS Letters 579(23), pp. 5193-5198. (10.1016/j.febslet.2005.08.037)
- McLoughlin, R. M. et al. 2005. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proceedings of the National Academy of Sciences of the United States of America (PNAS) ISSN 1091-6490 102(27), pp. 9589-9594. (10.1073/pnas.0501794102)
- Siebert, S., Amos, N., Fielding, C. A., Wang, E. C. Y., Aksentijevich, I., Williams, B. D. and Brennan, P. 2005. Reduced tumor necrosis factor signaling in primary human fibroblasts containing a tumor necrosis factor receptor superfamily 1A mutant. Arthritis & Rheumatism 52(4), pp. 1287-1282. (10.1002/art.20955)
- Fielding, C. A., Siebert, S., Rowe, M. and Brennan, P. 2004. Analysis of human tumour necrosis factor receptor 1 dominant-negative mutants reveals a major region controlling cell surface expression. FEBS Letters 570(1-3), pp. 138-142. (10.1016/j.febslet.2004.06.035)
- Richardson, C. J., Fielding, C., Rowe, M. and Brennan, P. 2003. Epstein-Barr virus regulates STAT1 through latent membrane protein 1. Journal of Virology 77(7), pp. 4439-4443. (10.1128/JVI.77.7.4439-4443.2003)
- Fielding, C. A., Sandvej, K., Mehl, A. M., Brennan, P., Jones, M. and Rowe, M. 2001. Epstein-Barr virus LMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways. Journal of Virology 75(19), pp. 9129-9141. (10.1128/JVI.75.19.9129-9141.2001)
Ymchwil
SARS-CoV-2
SARS-CoV-2 yw'r coronafirws newydd, sy'n achosi COVID-19. Mae ein canfyddiadau diweddar wedi nodi mecanwaith y mae SARS-CoV-2 yn gallu atal actifadu celloedd lladd naturiol (NK), math o gell imiwnedd, trwy atal cynhyrchu proteinau ('gewynnau actifadu') a fyddai'n eu actifadu. Mae'n ymddangos ei fod yn gwneud hyn trwy atal eu cyfieithu. Gellir goresgyn yr ataliad hwn o gelloedd NK gan wrthgyrff penodol SARS-CoV-2 sy'n bresennol mewn pobl sydd wedi gwella o COVID-19. Mae'r gwrthgyrff hyn yn adnabod sawl protein SARS-CoV-2 gwahanol sy'n bresennol ar wyneb y gell heintiedig, gan gynnwys Spike (S), Nucleocapsid (N), Pilen (M) ac Orf3a (Fielding et al., 2022, https://doi.org/10.7554/eLife.74489).
Cytomegalofirws
Yn fyd-eang, mae'r rhan fwyaf o bobl yn cael eu heintio â cytomegalofirws (CMV) heb sylweddoli hynny. Mae CMV yn perthyn yn agos i herpes simplex, y firws sy'n achosi briwiau oer. Fel herpes simplex, mae heintiau CMV am oes a rhaid eu rheoli'n gyson gan ein system imiwnedd. Mae clefyd yn digwydd pan fydd y rheolaeth hon yn chwalu. Mae clefyd CMV yn broblem fawr mewn ysbytai; Yn bennaf oherwydd ei allu i achosi heintiau sy'n peryglu bywyd mewn cleifion sydd wedi'u hatal ag imiwnedd, yn enwedig derbynwyr mêr esgyrn, aren a thrawsblaniad y galon ynghyd â chleifion â HIV-AIDS. Gall clefyd CMV amlygu mewn bron unrhyw organau (e.e. ysgyfaint, coluddyn, ysgyfaint, ymennydd, llygad, clust). Yn feirniadol, mae CMV yn gallu croesi'r brych i heintio'r ffetws, ac mae'n gwneud hynny mewn ~ 1% o feichiogrwydd. Gall haint cynhenid ysgogi camesgoriad, mae'n achos cyffredin o fyddardod ac yn ei ffurf fwy difrifol mae'n achosi niwed i'r ymennydd. Yn nhermau creulon, y gost mewn gofal cleifion yn unig yw $ 1.86 biliwn y flwyddyn yn yr UD. Mae clefyd cynhenid CMV yn sbarduno datblygiad brechlynnau. Yn fwy cynnil, mae haint CMV yn newid cyfansoddiad celloedd imiwnedd cludwyr ymddangosiadol iach ac nid yw goblygiadau hyn yn hysbys. Mae CMV yn bathogen dynol mawr y mae angen ymchwilio iddo ac mae'n haeddu proffil cyhoeddus llawer uwch.
CMV yw'r firws dynol mwyaf cymhleth sy'n cynnwys bron i 200 o enynnau, ac nid oes angen >124 o enynnau i efelychu'r firws. Mae ymchwil gennym ni, ac eraill, yn dangos bod llawer yn rheoli ein system imiwnedd. Gan fod y rhan fwyaf ohonom yn cario'r pathogen hwn trwy gydol ein hoes, mae'n bwysig darganfod beth mae'r genynnau hyn yn ei wneud. Er mwyn mynd i'r afael â'r mater hwn fe wnaethom ddiffinio genom yr asiant clinigol yn gyntaf ac yna datblygu systemau i sgrinio ar gyfer swyddogaeth genynnau CMV: gwnaethom gynhyrchu i) llyfrgell fector sy'n gallu mynegi pob genyn CMV mewn celloedd yn unigol a ii) panel o firysau CMV wedi'u dileu mewn blociau mawr o enynnau. Mae cyfuno'r adnoddau hyn wedi ein galluogi i fapio nifer sylweddol o swyddogaethau osgoi imiwnedd CMV yn gyflym. Fodd bynnag, byddem hefyd eisiau gwybod sut yr oeddent yn gweithio. Sefydlwyd cydweithrediadau gydag ymchwilwyr yn Harvard a Chaergrawnt i fanteisio ar systemau proteomig o'r radd flaenaf i olrhain mynegiant o arwyneb celloedd >700 a phroteinau mewngellol >7000 yn ystod heintiau firws. Mae'r technolegau hyn yn cyfuno i ddatgelu yn union sut mae genynnau osgoi imiwnedd CMV unigol yn gweithredu.
Mae celloedd Killer Naturiol (NK) yn gelloedd gwaed gwyn sy'n hanfodol wrth reoli clefyd CMV cytomegalofirws. Ar hyn o bryd rydym yn sgrinio pob genyn CMV yn systematig am eu gallu i fodiwleiddio swyddogaeth celloedd NK. Mae'r genom CMV wedi'i drefnu yn 'deuluoedd' o enynnau cysylltiedig sydd wedi codi trwy ddyblygu rhagflaenydd hynafol cyffredin. Nod ein hymchwil gyfredol yw nodweddu effaith dau deulu genynnau CMV (y teulu US12 a'r teulu RL11) ar yr ymateb imiwnedd i CMV, yn enwedig celloedd NK. Mae ein gwaith diweddar yn tynnu sylw at rôl y teulu US12 wrth reoleiddio swyddogaeth celloedd NK (Fielding et al., 2014, https://doi.org/10.1371/journal.ppat.1004058; Fielding et al., 2017, https://doi.org/10.7554/eLife.22206).
Addysgu
- Tiwtor ar gyfer Adolygu Llenyddiaeth SSC 1af Blwyddyn MBCH
- Tiwtor ar gyfer tiwtorialau firoleg 2il flwyddyn MBCH
- Darlithydd ac Aseswr ar gyfer ME3045 modiwl Imiwnoleg Ymlaen Llaw BSc a Patholeg Rhyng-gyfrifedig; 'Rhyngweithio firysau â'r system imiwnedd' ac 'Osgoi imiwnedd gan firysau'
- Darlithydd ar gyfer MSc Imiwnoleg Gymhwysol, Arbrofol a Chlinig; 'Gwrthfiraol' a phaogenesis 'COVID-19'
- Goruchwyliwr ac Aseswr ar gyfer Ffarmacoleg Prosiectau labordy BSc
- goruchwyliwr myfyrwyr PhD
Bywgraffiad
Trosolwg Gyrfa
- 2021-presennol: Darlithydd mewn Firoleg (CCAUC)
- 2011-2021: Ymchwil Ôl-ddoethurol, Prifysgol Caerdydd (grant prosiect 3x MRC, grant cydweithredol 1x Ymddiriedolaeth Wellcome)
- 2009-2010: Gwobr Gwerth mewn Pobl (Ymddiriedolaeth Wellcome)
- 2006-2009: Cymrawd Datblygu Gyrfa Ymchwil Arennau y DU
- 2003-2006: Ymchwil Ôl-ddoethurol, Prifysgol Caerdydd (Ymddiriedolaeth Wellcome)
- 2001-2003: Ymchwilydd Ôl-ddoethurol, Coleg Meddygaeth Prifysgol Cymru (Ymddiriedolaeth Leverhulme)
Addysg a Chymwysterau
- 1998-2001: PhD Firoleg Moleciwlaidd, Coleg Meddygaeth Prifysgol Cymru (Cronfa Ymchwil Lewcemia)
- 1998-1999: Diploma mewn Dulliau Biofeddygol, Coleg Meddygaeth Prifysgol Cymru
- 1994-1998: BSc (Anrh) gyda Firoleg Blwyddyn Rhyng-gyfrifedig, Prifysgol Warwick
Anrhydeddau a dyfarniadau
- Gwobr Haniaethol, Cynhadledd Cymdeithas Arennol (2010)
- Gwobr Sheldon Wolff am Ymchwil Cytokine, Cymdeithas Ryngwladol Cytokine (2004)
Aelodaethau proffesiynol
- Cymdeithas Microbioleg
- Cymdeithas Imiwnoleg Prydain
Pwyllgorau ac adolygu
- Cynrychiolydd Cymru, Pwyllgor Fforwm, Cymdeithas Imiwnoleg Prydain
- Trysorydd, Grŵp Rhanbarthol De Cymru Cymdeithas Imiwnoleg Prydain
Meysydd goruchwyliaeth
Mae gen i ddiddordeb mewn goruchwylio prosiectau ymchwil ar gyfer myfyrwyr BSc Biocemeg/Ffarmacoleg/Ffarmacoleg Feddygol (prosiectau blwyddyn olaf), myfyrwyr blwyddyn hyfforddi proffesiynol (PTY), myfyrwyr MSc a myfyrwyr PhD ym meysydd:
- Firoleg
- Imiwnoleg
Contact Details
FieldingCA@caerdydd.ac.uk
+44 29225 10233
Adeilad Henry Wellcome ar gyfer Ymchwil Biofeddygol, Ystafell UG17, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
+44 29225 10233
Adeilad Henry Wellcome ar gyfer Ymchwil Biofeddygol, Ystafell UG17, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
